Great Wall Motor Shares Drop After Flagging Lower 2023 Profit
By Jiahui Huang
Great Wall Motor's shares dropped sharply after the Chinese automaker said it expected profit to fall 15% in 2023, with fourth-quarter profit also declining sequentially.
Hong Kong-listed shares fell 9.2% at midday Wednesday, taking losses this month to 20%. The company's China-listed shares were down 3.0% on the Shanghai Stock Exchange.
Great Wall Motor said in a release of preliminary 2023 results Tuesday that it expects full-year net profit to fall 15% to 7.01 billion yuan (US$980.9 million), even as its topline likely rose 26% on higher selling prices and demand. It blamed the lower profit on foreign currency movements, without elaborating.
The Hebei, China-based company said it also expects fourth-quarter profit to have fallen on a sequential basis, which it attributed to expenditure on annual staff bonuses.
Citi Research analyst Jeff Chung said in a note that the full-year revenue beat his estimates, and that fourth-quarter profit was "decent," even as it came in lower than forecast due to "very high" year-end bonuses and one-off items.
Chung kept his buy rating and HK$12.50 target price for the stock, noting that the company remains one of the bank's sector picks in 2024.
He also maintained his forecast for 2024 profit of CNY10.8 billion, up more than 54% from the preliminary 2023 figure.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
January 23, 2024 23:43 ET (04:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth